Clinical Trial Update: A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer [Phase 1]

View source ↗

Summary

Phase 1 study of oral PF-02341066 (crizotinib) as a tyrosine kinase inhibitor targeting c-Met/HGF pathway in advanced cancers; study completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignancies
• Non-small Cell Lung Cancer
• Systemic Anaplastic Large Cell Lymphoma

Drugs mentioned

• PF-02341066 (PF-02341066)

Snippet

Sponsor: Pfizer | Conditions: Non-Small Cell Lung Cancer ALK-positive, Non-Small Cell Lung Cancer c-Met Dependent | Phase 1 | Status: COMPLETED | Results posted: 2021-10-14